The effects of two vitamin D regimens on ulcerative colitis activity index, quality of life and oxidant/anti-oxidant status

Sara Karimi¹, Sanam Tabataba-vakili², Zahra Yari³, Forough Alborzi⁴, Mehdi Hedayati⁴, Nasser Ebrahim-Daryani³ and Azita Hekmatdoost¹*

Abstract

Background: The optimum dosage for vitamin D supplementation has not yet been elucidated in patients with Ulcerative colitis (UC). The aim of this study was to investigate the effects of two vitamin D regimens in UC patients with vitamin D deficiency.

Methods: In this double blind randomized clinical trial, 50 patients with mild to moderate UC, who met inclusion criteria, received either 1000 or 2000 IU/day of vitamin D (as low dose or high dose group, respectively) for 12 weeks. Serum 25-hydroxy vitamin D (25-OHD) level, total antioxidant capacity (TAC), and Total Oxidant Status (TOS), the inflammatory bowel disease questionnaire – 9 (IBDQ-9) score and the Simple Clinical Colitis Activity Index Questionnaire (SCCAI) score were assessed before and after intervention.

Results: At the end of study, serum 25-OHD levels significantly increased in the high dose group ($P < 0.001$) and the increase was significantly more than low dose group ($6.7 ± 3.8$ ng/mL in the high dose group versus $0.2 ± 0.5$ ng/mL in the low dose group) ($P < 0.001$). Serum TOS concentration decreased significantly ($−0.37 ± 0.26$) only in the high dose group ($P$ value = 0.023). There was no statistically significant change in serum TAC between two groups during the study. IBDQ-9 mean score significantly increased in high dose group compared to the low dose group ($P$ value = 0.001) and SCCAI score in both groups reduced ($−2.58 ± 2.16$ and $−0.9 ± 0.3$ in high dose and low dose respectively), while this reduction was significant only in the high dose group ($P$ value $≥0.001$).

Conclusion: Our results indicate that 2000 IU daily dose of vitamin D can increase serum 25-OHD concentration, and quality of life, while it reduces disease activity in UC patients with vitamin D deficiency. We recommend assessment of the vitamin D status in all patients with UC because they may benefit from vitamin D therapy.

Keywords: Ulcerative colitis, Inflammatory bowel disease, Vitamin D, Oxidative stress

Introduction

Inflammatory bowel disease (IBD) is a type of immune-mediated chronic bowel disorder including Ulcerative colitis (UC) and Crohn’s disease (CD) [1]. The etiology of IBD is not completely understood; however, increasing evidence have shown the role of genetic and environmental factors on immunopathologic processes of disease [2–8].

The incidence and prevalence of IBD is increasing over time in western countries and in different parts of the world [9]. The prevalence of UC in Europe and North America has been reported to be 505 and 249 out of every 100,000 persons, respectively [10]. Although little epidemiological information of developing countries is available, recent studies indicate that this disease is rapidly increasing in many developing countries as well as Africa, South America and Asia [9–11]. In spite of significant advances in the treatment of this disease, no definitive treatment has yet been found so far and the aim of existing treatments is to reduce symptoms, prolongation of disease remission and improvement in patients’ quality of life.
These medications have serious side effects such as increasing the risk of infection, increasing the sensitivity and risk of mutagenesis, which limits their therapeutic value [1, 12–14].

Vitamin D has been linked to a wide range of physiological functions including immune responses [15]. Vitamin D deficiency has been associated with various immunological diseases such as allergies and autoimmune diseases. Different mechanisms for the effects of vitamin D on inherent and acquired immune systems are supposed to reduce inflammation, promote immunological tolerance, and increase the intestinal epithelial integrity [16].

Several studies have been conducted to evaluate the efficacy of vitamin D in IBD patients and in some of them a link between vitamin D deficiency and disease activity, mortality and severity of the disease, its early onset and risk of recurrence was found [17–22]; however, the optimum dosage for supplementation has not yet been elucidated.

Thus, we designed this study to determine the effects of two dosages of vitamin D supplementation on serum vitamin D, total antioxidant capacity (TAC), total oxidant status (TOS), quality of life, and disease activity index in patients with UC.

Materials and methods

Study design

This study is a double blind randomized clinical trial, which included patients with mild to moderate UC [14] referring to Shahid Fayyaz-Bakhsh Hospital, and a private gastroenterology clinic, who fulfilled the inclusion criteria of the study. At the beginning of the study, the goals and methods of the study were explained to patients. Out of 77 patients, 65 UC patients were interviewed and 50 patients were willing to take part in our study (Fig. 1). Written consent approved by the ethics committee of the National Nutrition and Food Technology Research Institute (NNFTRI), Shahid Beheshti University of Medical Sciences.

Fig. 1 Patients’ recruitment flow chart
Sciences (SBMU), Tehran, Iran, was obtained from all patients. A general demographic questionnaire was completed for each patient. Meanwhile, the inflammatory bowel disease questionnaire-9 (IBDQ-9) and the Simple Clinical Colitis Activity Index Questionnaire (SCCAIQ) were completed. [14]. The IBDQ-9 questionnaire was designed by Casellas et al. [23]. To measure the quality of life affected by IBD from the original IBD questionnaire. This questionnaire contains 9 questions, which like the original version, assesses the condition from the four dimensions of gastrointestinal, systemic, emotional and social disturbances. The answer to each question has 7 choices that range from 1 (the worst) to 7 (the best). The patient should mark one of the options as the best answer for each question, and the total score is 9 to 63. The higher score represents a better quality of life in patients. It is worth noting that this questionnaire has been linguistically validated for Iranian patients [24]. SCCAI-Q which is suitable for evaluation of patients with UC is a clinical activity indicator and consists of 6 questions, scaled from zero to 18.

In order to evaluate patients’ dietary intakes, three 24-h food recalls on one holiday and two working days were completed through telephone or in-person interviews at the beginning and end of study. Patients were asked not to change their diet and physical activity during the study period. The analysis of 24-h food recall questionnaires was done using Nutritionist IV (N4) (First Databank, Hearst Corp, San Bruno, CA, USA).

**Ethical considerations**

This study was conducted in accordance with principles of the medical ethics committee of National Nutrition and Food Technology Research Institute, No.1395.110, and has been registered at the Iranian Center for Clinical Trials (No. IRCT 20100524004010 N22).

**Study participants**

Patients with active mild to moderate UC, whose disease had been confirmed pathologically, were recruited for this study. The inclusion criteria included: histopathologic diagnosis of mild to moderate (diagnosis of the severity of the disease was based on physician’s judgment), vitamin D deficiency (< 30 ng/mL), the absence of other diseases, intestinal disorders, known autoimmune diseases, cancer, inflammatory and infectious diseases, not using vitamin D supplements, mineral-multivitamins, omega-3, polyphenolic and antioxidant medications, and not using of anticoagulants such as Heparin and Warfarin, non-steroid anti-inflammatory drugs such as Ibuprofen, Aspirin and Diclofenac, Antihistamines and calcium channel antagonists such as Nifedipine during the past month, age ≥ 18, and no change in the type and dosage of their medicine over the past month. The exclusion criteria included pregnancy or breastfeeding or using contraceptives in women, patient’s unwillingness to continue study protocol, changes in the type and dosage of the drug during the study.

**Interventions**

In this study, participants were randomly divided into two groups to receive either a high-dose or a low-dose vitamin D supplement. Patients received the supplements for 12 weeks [14, 25], based on their group assignment. Participants in high dose group, received 2 capsules of 1000 IU vitamin D daily [25]. Patients in the low dose group were given 1 capsule of 1000 IU of vitamin D supplements and 1 capsule of placebo daily, which were apparently similar to each other. Supplement capsules were purchased from Zahraei Company. For blinding the study supplements, the boxes containing the capsules were coded as A, B and C, by a person other than the researchers. All of the patients received a box of A, but according to the fact that patients in the group receiving a high or a low dose of vitamin D supplementation, boxes B or C were given to them, as vitamin D or placebo capsules. Therefore, patients received 2000 IU vitamin D or 1000 IU vitamin D plus a placebo capsule. Patients’ compliance was assessed using capsules count remained in the box at each visit (6th, and 12th week of the intervention).

**Measurements**

At first, and 12th week of study, the weight of each patient was measured in light weight clothing, with accuracy of 100 g and height measurement of each patient without shoes was performed by meters mounted on a wall with a 1 cm accuracy. Then the body mass index (BMI) was calculated. After 9–12 h of fasting, 5 cc blood samples were taken from each patient and their serum was kept in the − 80°C freezer until serum measurement analysis. IBDQ-9 and SCCAIQ were filled out at the beginning and the end of study. Serum concentrations of TAC, TOS and 25- hydroxyl vitamin D (25-OHD) concentration were measured using ELISA method (ZellBio GmbH, Ulm, Germany) [14, 23, 26, 27].

**Statistical analysis**

Data are presented as (mean ± standard deviation) and frequency (percentages) for quantitative and qualitative variables, respectively. Normal distribution of data was evaluated using Kolmogorov-Smirnov test. Chi-Square test was used to compare the qualitative confounding variables of the two groups. To compare the mean of quantitative variables in each group (if their distribution was normal) paired t-test was used for double-measured data and comparison of their mean between two groups was evaluated by Student’s t-test.
Results
Fifty patients (25 in the high dose group and 25 in the low dose group) took part in our study. A total of 46 patients, including 24 patients in the high dose group (52.2%) and the 22 patients in the low dose group (47.8%) completed the study and 4 patients lost to follow-up; the reasons for the withdrawal of patients from both groups are shown in Fig. 1. There was no significant difference in the dropout rate between two groups (P-value = 0.609). In general, the participation rate in this study was 92%.

As shown in Table 1, there was no significant difference in the distribution of sex as well as age and length of the disease between high dose and low dose group at the beginning of the study (Table 1). Comparison of BMI and medications during the study did not show any significant difference in each group (Table 2). All patients used Masalamine at the beginning and the end of study. Forty one percent of participants in low dose group and 16.6% in high dose group took Azathioprine (p = 0.55). Corticosteroids were used by 12.5, and 13.6% of patients in high dose and low dose groups, respectively (p = 1). Moreover, there was no significant difference between the two groups in terms of calorie intake and dietary components.

Serum 25-OHD level was not significantly different between two groups at the beginning (p = 0.37), and the end of study (p = 0.93). In the high dose group, serum 25-OHD significantly increased during the study, while this increase was not significant in the low dose group (Table 3). The mean changes in low dose and high dose groups were 0.2 ± 2.2 and 6.7 ± 3.8 respectively, which was significantly higher in high dose group compared with low dose group (p < 0.0001).

Table 1 The duration of the disease and individual characteristics of the patients participated in two groups receiving high and low doses of vitamin D before intervention *

| Variables                  | Low dose group | High dose group | P-value |
|----------------------------|----------------|-----------------|---------|
| Gender (n(%))              |                |                 |         |
| Men                        | 11 (50)        | 13 (54.2)       | 1*      |
| Women                      | 11 (50)        | 11 (45.8)       |         |
| Age (years)                | 39.72 ± 15.56  | 34 ± 12.48      | 0.174*  |
| Men                        | 35.00 ± 14.89  | 33.31 ± 14.62   | 0.782** |
| Women                      | 44.45 ± 15.41  | 34.82 ± 10.02   | 0.098** |
| Duration of disease (years)| 7.18 ± 1.15    | 4.04 ± 0.97     | 0.083*  |
| Men                        | 6.18 ± 2.18    | 4.07 ± 1.39     | 0.408** |
| Women                      | 8.18 ± 2.15    | 4.01 ± 1.42     | 0.122** |
| Extension of Disease (n (%))|                |                 | 0.97*   |
| Proctitis                  | 7 (32)         | 7 (30)          |         |
| Left side                  | 14 (63)        | 16 (66)         |         |
| Pancolitis                 | 1 (4)          | 1 (4)           |         |

*The values for age and duration of the disease are reported as mean ± SD and the others reported as number (percentages)
*Variables test between the two groups separated by gender
*Fisher’s Exact Test
*Student’s t-test

Table 2 Body mass index and medications in patients participated in two groups receiving high and low doses of vitamin D in the beginning and the end of the study *

| Variables               | Time of the study | P-value |
|-------------------------|-------------------|---------|
| Body mass index (kg/m²) |                   |         |
| High dose group         | 24.29 ± 3.61      | 24.69 ± 3.34 | 0.087 |
| Low dose group          | 25.56 ± 4.27      | 25.69 ± 4.39 | 0.192 |
| P-valueb                | 0.284             | 0.382   |
| Dose of Azathioprine (mg/day) |       |         |
| High dose group         | 87.50 ± 25        | 87.50 ± 25 | 1     |
| Low dose group          | 83.33 ± 35.35     | 83.33 ± 35.55 | 1    |
| P-valueb                | 0.837             | 0.837   |
| Dose of Corticosteroid (mg/day) |        |         |
| High dose group         | 2.5 ± 7.3         | 0.9 ± 2.5 | 0.16  |
| Low dose group          | 0.2 ± 1.0         | 0       | 0.32  |
| P-valueb                | 0.16              | 0.10    |
| Dose of Mesalamine (mg/day) |            |         |
| High dose group         | 2473.68 ± 1123.90 | 2450 ± 1099.04 | 0.331 |
| Low dose group          | 2523.81 ± 872.87  | 2523.81 ± 872.87 | 0.696 |
| P-valueb                | 0.875             | 0.813   |

* Values are reported as Mean ± standard deviation
*a within groups; b between groups
Serum concentrations of TOS and TAC, oxidant/antioxidant concentrations did not change significantly in any of the two groups during the study.

In the high dose group, serum TOS concentration increased significantly ($P = 0.023$) compared to the low dose group; however, this significance was eliminated after adjusting for confounders ($P = 0.514$). The change in serum TAC concentration between two groups during the study was not statistically significant and remained unchanged after adjusting for confounders (Table 4).

As shown in Table 5, the mean score of IBDQ-9 after vitamin D supplementation significantly increased in both groups compared to baseline value. In the high dose group, the IBDQ-9 mean score showed a significant increase compared to the low dose group ($P = 0.001$), which remained significant after adjusting for confounding factors ($p = 0.045$). The SCCAI score in both high dose and low dose groups was reduced at the end of the study compared to the beginning of the study ($P = 0.009$, and $p \geq 0.001$, respectively). In the high dose group, the SCCAI mean scores in comparison with the low dose group showed a significant decrease ($P = 0.004$), which remained significant after adjustment for confounders ($p = 0.045$).

### Table 3

Mean and standard deviation of vitamin D levels in patients participated in two groups taking high and low doses of vitamin D at the beginning and end of the study

| Variables                  | Time of the study | $P$-value $^a$ |
|----------------------------|-------------------|----------------|
|                            | Beginning of study | End of study   |
| Serum 25-hydroxy vitamin D (ng/mL) |                    |                |
| High dose group            | 21.83 ± 9.69       | 28.99 ± 8.69   | $<0.001$ |
| Low dose group             | 24.37 ± 8.14       | 28.75 ± 11.90  | 0.192   |
| $P$-value $^b$             | 0.377              | 0.936          |

* Values are reported as Mean ± standard deviation
$^a$within groups; $^b$ between groups

Serum concentrations of TOS and TAC, oxidant/antioxidant concentrations did not change significantly in any of the two groups during the study.

In the high dose group, serum TOS concentration increased significantly ($P = 0.023$) compared to the low dose group; however, this significance was eliminated after adjusting for confounders ($P = 0.514$). The change in serum TAC concentration between two groups during the study was not statistically significant and remained unchanged after adjusting for confounders (Table 4).

As shown in Table 5, the mean score of IBDQ-9 after vitamin D supplementation significantly increased in both groups compared to baseline value. In the high dose group, the IBDQ-9 mean score showed a significant increase compared to the low dose group ($P = 0.001$), which remained significant after adjusting for confounding factors ($p = 0.045$). The SCCAI score in both high dose and low dose groups was reduced at the end of the study compared to the beginning of the study ($P = 0.009$, and $p \geq 0.001$, respectively). In the high dose group, the SCCAI mean scores in comparison with the low dose group showed a significant decrease ($P = 0.004$), which remained significant after adjustment for confounders ($p = 0.045$).

### Table 4

Mean and standard deviation of serum total oxidative and anti-oxidative capacity in patients participated in two groups taking high and low doses of vitamin D at the beginning and end of the study

| Variables | Time of the study | $P$-value $^c$ | $^ap$-value   | $^bp$-value   |
|-----------|-------------------|----------------|--------------|--------------|
|           | Beginning of study | End of study   |              |              |
| Serum TOS (ng/mL) |                    |                |              |              |
| Low dose group        | 2.94 ± 1.05        | 3.03 ± 0.80    | 0.70         | 0.209        |
| High dose group       | 3.37 ± 0.96        | 2.99 ± 1.00    | 0.17         | 0.599        |
| $P$-value $^d$        | 0.15               | 0.90           |              |              |
| Serum TAC (pg/mL)    |                    |                |              |              |
| Low dose group        | 0.57 ± 0.11        | 0.56 ± 0.12    | 0.47         |              |
| High dose group       | 0.57 ± 0.13        | 0.56 ± 0.09    | 0.30         |              |
| $P$-value$^d$        | 0.93               | 0.86           |              |              |

The values are reported as mean ± standard deviation
$^aP$–value for complementary efficacy (changes comparison) by Student T-test
$^bp$-value for complementary efficacy (changes comparison) after adjustment by ANCOVA test for BMI, and baseline values
$^cP$ –value for within group comparison using paired t test
$^dP$–value for between groups comparison using Student T-test
in both groups increased compared to the beginning of the study at weeks 8 and 12. Papa et al. [25] evaluated the effects of daily dose of 2000 IU vitamin D2 (control), and daily dose of 2000 IU vitamin D3 and weekly dose of 50,000 IU vitamin D2 in pediatric patients with IBD. Their results showed that oral doses of 2000 IU vitamin D3 daily and 50,000 IU of vitamin D3 per week were superior to daily dose of 2000 IU vitamin D2 and were better tolerated in children and adolescents with IBD.

Moreover, our results showed that both doses of vitamin D improved patients’ quality of life; however, level of disease activity only reduced by daily dose of 2000 IU. Although no clinical trial has reported the effects of vitamin D on disease activity and patients’ quality of life, the results of cross-sectional studies showed that the clinical activity and quality of life of IBD patients had a significant relationship with lower levels of vitamin D [20, 35].

A South African cohort study on Crohn’s disease found a relation between low levels of vitamin D and increased activity of the disease [19]. In two other studies, it has been shown that low levels of vitamin D are common in IBD patients, which has been associated with mortality and severity of the disease as well as the early onset of it, which could indicate the importance of the role of this vitamin in the improvement of these patients [20, 35]. Another study showed that levels of 35 ng/mL or less of serum vitamin D during the treatment period would increase the risk of recurrence of UC [21].

Although previous studies have shown that high levels of vitamin D is associated with low frequency of relapses [36], it is not known that blood vitamin D affects the disease relapse, or disease activity affects vitamin D status?

Vitamin D deficiency is associated with various immunological diseases, such as allergies and autoimmune diseases. Different mechanisms for the effects of vitamin D on the inherent and acquired immune system are intended to reduce inflammation, promote immune tolerance, and increase the integrity of the intestinal epithelium [16]. Vitamin D is involved in the regulation of the immune system and may play a pivotal role in the pathogenesis of IBD and it is considered as a contributing factor in the treatment of IBD [25].

Our results showed that daily dose of vitamin D does not have any significant effect on oxidative stress status. Vitamin D plays an important role in a wide range of physiological functions including immune responses [15]. Vitamin D inhibits several pro-inflammatory pathways [37, 38], modifies autophagy [38], reduces the oxidative stress [39], the differentiation and activation of the white blood cells [38, 40, 41] and increases the expression of tight junctions in the intestinal epithelium, thereby affecting mucosal permeability and tissue integrity [42].

Based on experimental studies, vitamin D receptor (VDR) and its ligands have an important effect on IBD disease [43]. Cantorna et al. [44] reported that mice with both vitamin D and IL-10 deficiency showed more acute enterocolitis at their 7th week of life. These authors reported that VDR plays an important role in capacity of colonic epithelium healing.

Wang et al. [45] showed that vitamin D deficiency exacerbates oxidative stress in obese patients. Vitamin D plays an anti-oxidative role through the regulation of oxidative stress reducing proteins [46, 47]. In this study, the primary level of oxidative stress was low, and this might be the reason of not observing a significant effect of vitamin D on oxidant and antioxidant concentrations.

The strength of the current study is evaluation of the effects of two doses of vitamin D supplements on serum 25-OHD levels, oxidative factors, quality of life, and disease activity index in adult patients with active mild
to moderate UC as the first double-blind randomized clinical trial.

Our study has some limitations. It may be necessary to use vitamin D for a longer time or in higher doses in order to observe its effects on oxidative stress status. Another limitation of our study was the lack of a healthy control group to compare the results with the healthy individuals. Moreover, we did not measure systemic phlogosis markers in this study; however, we assessed the oxidative stress status and disease activity which are correlated with systematic inflammation.

**Conclusion**

In conclusion, this study revealed that vitamin D supplementation with 2000 IU / day for 12 weeks could lead to an increase in serum 25-OHD levels, improvement of quality of life, and decrease in the disease activity index in adult patients with active mild to moderate UC, while supplementation with vitamin D of 1000 IU / day for 12 weeks, only improved the quality of life of patients. In both groups, the serum levels of TAC and TOS patients were not affected significantly.

**Abbreviations**

25(OH)2D: 25-hydroxyvitamin D; BMI: Body mass index (Kg/m2); CD: Crohn's disease; IBD: Inflammatory bowel disease; IBDQ-9: Inflammatory bowel disease questionnaire-9; IU: International units; SCCAQI: Simple Clinical Colitis Activity Index Questionnaire; TAC: Total anti-oxidant status; TOS: Total oxidant status; UC: Ulcerative colitis

**Acknowledgements**

We acknowledge contribution of all patients who accepted to participate in this study.

**Funding**

The study was supported by Shahid Beheshti University of Medical Science.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

SK and AH developed the proposal, obtained ethical approvals, applied for funding, supervised data collection and prepared the first draft. AH conceived the idea, provided expertise in designing and analysis of the study, FA and NED served as expert in IBD and contributed to the concept development and in the patients recruitment. ST, ZY, and MH were involved in study analysis. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Ethical clearance was taken from the National Nutrition and Food Technology Research Institute (NNFTRI). Informed consent was taken from all participants.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology, Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
2. Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3. Division of Gastroenterology, Imam Khomeini Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
4. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

**Received:** 18 December 2018 **Accepted:** 4 March 2019 **Published online:** 11 March 2019

**References**

1. Liu X, Wang J. Anti-inflammatory effects of iridoid glycosides fraction of folum syringae leaves on TNBS-induced colitis in rats. J Ethnopharmacol. 2011;133(2):780–7.
2. Monteleone I, Pallone F, Monteleone G. interleukin-23 and Th17 cells in the control of gut inflammation. Mediat Inflamm. 2009;2009:1–7.
3. Hekmatdoost A, et al. The effect of dietary oils on cecal microflora in experimental colitis in mice. Indian J Gastroenterol. 2008;27(5):186–9.
4. Hekmatdoost A, et al. Polysaturated fatty acids, microflora and colitis. Ann Nutr Metab. 2009;55(4):325.
5. Hekmatdoost A, et al. Dietary oils modify the host immune response and colonic tissue damage following Citrobacter rodentium infection in mice. Am J Physiol Gastrointest Liver Physiol. 2013;304(10):G917–28.
6. Rashvand S, et al. Dietary protein intakes and risk of ulcerative colitis. Med J Islam Repub Iran. 2015;29:253.
7. Rashvand S, et al. Dietary fatty acid intakes are related to the risk of ulcerative colitis: a case–control study. Int J Color Dis. 2015;30(9):1255–60.
8. Shivappa N, et al. Inflammatory potential of diet and risk of ulcerative colitis in a case–control study from Iran. Nutr Cancer. 2016;68(3):404–9.
9. Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–78.
10. Molodecky NA, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42.
11. Sherkat R, et al. Establishment and development of the first biobank of inflammatory bowel disease, suspected to primary immunodeficiency diseases in Iran. Adv Biomed Res. 2018;7:45. https://doi.org/10.4103/abrar.abrar_278_16. eCollection 2018.
12. Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17(s1):S1–6;S1–S85.
13. Samsamikor M, et al. Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res. 2016; 47(4):304–9.
14. Samsami-kor M, et al. Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res. 2015;46(4):280–5.
15. Meeker S, et al. Protective links between vitamin D, inflammatory bowel disease and colon cancer. World J Gastroenterol. 2016;22(3):933.
16. Suaini NH, et al. Immune modulation by vitamin D and its relevance to food allergy. Nutrients. 2015;7(8):6088–108.
17. Del Pinto R, et al. Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(11):2708–17.
18. Torki M, et al. Vitamin D deficiency associated with disease activity in patients with inflammatory bowel diseases. Dig Dis Sci. 2015;60(10):3085–91.
19. Raffner Basson A, et al. Vitamin D deficiency increases the risk for moderate to severe disease activity in Crohn’s disease patients in South Africa, measured by the Harvey Bradshaw index. J Am Coll Nutr. 2016;35(2):163–74.
20. Kabbani TA, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study. Am J Gastroenterol. 2016;111(5):712.
21. Gubatan J, et al. Low serum vitamin D during remission increases risk of clinical relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2017;15(2):240–6 e1.
22. Ananthakrishnan AN. Editorial: vitamin D and IBD: can we get over the “causation” hump? Am J Gastroenterol. 2016;111(5):720–2.
23. Casellas F, et al. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol. 2004;99(3):457–61.
24. Gholamrezaei A, et al. Linguistic validation of the inflammatory bowel disease questionnaire-short form (IBDQ-9) in Iranian population. J Isfahan Med Sch. 2011;28(123).
25. Pappa HM, et al. Treatment of vitamin D insufficiency in children and adolescents with inflammatory bowel disease: a randomized clinical trial comparing three regimens. J Clin Endocrinol Metab. 2012;97(6):2134–42.
26. Walmsey RS, et al. A simple clinical colitis activity index. Gut. 1998;43(1):29–32.
27. Verissimo R. Quality of life in inflammatory bowel disease: psychometric evaluation of an IBDQ cross-culturally adapted version. J Gastrointestin Liver Dis. 2008;17(4):439–44.
28. National Institutes of Health. Vitamin D fact sheet for health professionals. 2018. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/#en1.
29. Farraye FA, et al. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent crohn’s disease. Inflamm Bowel Dis. 2011;17(10):2116–21.
30. Lo CW, et al. Vitamin D absorption in healthy subjects and in patients with intestinal malabsorption syndromes. Am J Clin Nutr. 1985;42(4):644–9.
31. Margulies SL, et al. Vitamin D deficiency in patients with intestinal malabsorption syndromes – think in and outside the gut. J Dig Dis. 2015;16(1):167–33.
32. Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;39(2):125–36.
33. Ananthakrishnan AN. Vitamin D and inflammatory bowel disease. Gastroenterol Hepatol. 2016;12(8):513–5.
34. Simsek RZ, et al. A pilot study evaluating efficacy of two dosing regimens for repletion of hypovitaminosis D in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;62(2):252–8.
35. Castro FD, et al. Lower levels of vitamin D correlate with clinical disease activity and quality of life in inflammatory bowel disease. Arq Gastroenterol. 2015;52(4):260–5.
36. Hanauer SB. Vitamin D levels and outcomes in inflammatory bowel disease– which is the chicken and which is the egg? Clin Gastroenterol Hepatol. 2017;15(2):247–8.
37. Wu S, et al. Vitamin D receptor negatively regulates bacterial-stimulated NF-kB activity in intestine. Am J Pathol. 2010;177(2):686–97.
38. Verway M, Behr MA, White JH. Vitamin D, NOD2, autophagy and Crohn’s disease. Expert Rev Clin Immunol. 2010;6(4):505–8.
39. Polidoro L, et al. Vitamin D protects human endothelial cells from H 2 O 2 oxidant injury through the Mek/Erk-Sirt1 axis activation. J Cardiovasc Transl Res. 2013;6(2):221–31.
40. Cantorna MT. Why do T cells express the vitamin D receptor? Ann N Y Acad Sci. 2011;1217(1):77–82.
41. Konietz KG, et al. Sa1779 Vitamin D modulates T cell-mediated immunity: results from a randomized controlled trial of low-dose and high-dose vitamin D3. Gastroenterology. 2014;146(5):S294–5.
42. Kong J, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucusal barrier. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G208–16.
43. Ulltqvist A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. J Parenter Enter Nutr. 2011;35(3):308–16.
44. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med. 2004;229(1):1136–42.
45. Wang EW, et al. Vitamin D deficiency, oxidative stress and antioxidant status: only weak association seen in the absence of advanced age, obesity or pre-existing disease. Br J Nutr. 2017;118(1):116.
46. Ibi M, et al. Protective effects of tca, ZS-O-CH 2 D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology. 2001;40(6):761–71.
47. Ting H-J, Lee Y-F. Vitamin D and oxidative stress. In: Vitamin D: oxidation, immunity, and aging. Boca Raton: Taylor & Francis Group, CRC Press; 2012. p. 131–49.